A Phase 1 interventional study of Metformin immediate release (IR) and Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Terminated at 7 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 274th largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 55 in phase 1, and was the 145th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 23 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 277th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2012, is one of 86 in phase 1, and was the 205th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets
The primary purpose is to assess the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects aged 10 to 17 years with T2DM following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Metformin immediate release (IR) · Drug: Saxagliptin · Drug: Metformin IR · Drug: Saxagliptin/Metformin XR FDC · Drug: Metformin XR
Tablet, Oral, 1000 mg, twice daily, 1 day
Also known as: Glucophage® IR
Tablet, Oral, 5 mg, single-dose, 1 day
Tablet, Oral, 1000 mg, twice daily, 5 days
Also known as: Glucophage® IR
Drug pages: Saxagliptin · Metformin
Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
Tablet, Oral, 500 mg, Single-dose of 4 tablets
Also known as: Glucophage® XR
Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: Day 1 up to Day 8, plus 30 days
Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities
Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-RX \>ULN or \>1.25\*ULN if Pre-RX \<=ULN; aspartate aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;alanine aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;blood urea nitrogen mmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.2\*Pre-RX if Pre-RX \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.25\*Pre-RX if Pre-RX \>ULN; creatine phosphokinase U/L: \>1.5\*Pre-RX if Pre-RX\>ULN or \>1.5\*ULN if Pre-RX \<= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (%): \<0.85\*pre-RX;erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN.
Time frame: Day 1 to Day 8
Upon approval of Kombiglyze™ XR, the Food and Drug Administration (FDA) required the conduct of this clinical pharmacology study in pediatric patients as a post-marketing requirement (PMR). Study was initiated February 2013. On 14-Nov-13, the FDA issued a letter stating release from this PMR, thus the study was terminated prior to completion.
| Milestone | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| Started | 4 |
| Completed | 2 |
| Not completed | 2 |
| Withdrew: No longer met study criteria | 1 |
| Withdrew: Other | 1 |
| Milestone | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| Started | 2 |
| Completed | 2 |
| Not completed | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| participants | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| AE | 2 |
| Treatment-Related AE | 1 |
| AE Leading to Discontinuation | 0 |
| SAE | 0 |
| Death | 0 |
Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-RX \>ULN or \>1.25\*ULN if Pre-RX \<=ULN; aspartate aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;alanine aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;blood urea nitrogen mmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.2\*Pre-RX if Pre-RX \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.25\*Pre-RX if Pre-RX \>ULN; creatine phosphokinase U/L: \>1.5\*Pre-RX if Pre-RX\>ULN or \>1.5\*ULN if Pre-RX \<= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (%): \<0.85\*pre-RX;erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN.
| participants | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities | 0 |
Collected over Day 1 up to Day 8, plus 30 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC | — | 0/2 (0%) | 2/2 (100%) |
| Event | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| HeadacheNervous system disorders | 2/2 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| Median | 13.0 (10.0 to 16.0) |
| Sex: Female, Male(Participants) | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| Female | 2 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| Black/African American | 1 |
| White | 1 |
| Region of Enrollment(participants) | Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC |
|---|---|
| United States | 2 |
The record gives a start of Sep 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Saxagliptin